A method and apparatus for disrupting material at a tissue site is described. The apparatus includes a modulating layer formed from an open-cell reticulated foam and positionable adjacent the tissue site. The apparatus also includes a macro-column layer formed from a felted foam and having a plurality of through-holes separated from each other by walls. The macro-column layer is positionable adjacent to the modulating layer. The through-holes form nodules in the tissue site in response to negative pressure.

A wound dressing includes an elastic foam layer, a drape layer, and superabsorbent projections. The elastic foam layer is configured to engage a wound bed and has a first side and a second side, the second side configured to face the wound bed. The drape layer also has a first side and a second side, the second side configured to face the first side of the elastic foam layer. The elastic foam layer also has a plurality of superabsorbent projections (nodules, dots, bumps, lumps, islands, protuberances) fixed to and extending from the first side of the elastic foam layer towards the second side of the drape layer.

An apparatus for promoting circulation through a subcutaneous lymph vascular network may comprise a first manifold layer, a second manifold layer coupled to the first manifold layer, and a cover layer coupled to the second manifold layer. The first manifold may have a first stiffness, and the second manifold may have a second stiffness greater than the first stiffness. In some embodiments, the apparatus may additionally have a fluid interface configured to fluidly couple at least one of the first manifold layer and the second manifold layer to a fluid conductor through the cover layer. The fluid conductor may be coupled to or configured to be coupled to a source of negative pressure.

In some illustrative examples, a bridge suitable for treating a tissue site may include a bridge sealing member and one or more bridge wicking layers. The bridge sealing member may extend along a length of the bridge, and may define an internal passageway in fluid communication between a receiving end of the bridge and a transmitting end of the bridge. The one or more bridge wicking layers may be disposed within the internal passageway of the bridge sealing member. Other apparatus, systems, and methods are disclosed.

The present invention relates to a pad for treating skin diseases, comprising agar gel and a fiber layer fixed to the inside of the gel, and a manufacturing method therefor. The pad of the present invention inhibits blood vessel exudation symptoms according to vasodilation by maintaining a low temperature of the affected area, reduces an itchy sensation and, at the same time, removes, from the skin, plasma proteins and various plasma-derived substances accumulated in skin tissue, thereby having an effect of alleviating the symptoms of the affected area.

The present invention relates to a medical dressing that has a modular structure consisting of at least two layers and that is able to cleave incorporated photolabile nitric oxide donors in an adjoining absorption module by means of the emission of electromagnetic radiation from a light module, so that the photolytically generated nitric oxide can be used to enhance medical therapies in humans and animals as well as to generate NO.

An absorbent stoma pad for encapsulating an external bolster of a feeding tube is provided. The stoma pad includes an upper layer, base layer, absorbent material, and cavity. The upper layer, which includes an upper surface and a lower surface, contains a centrally located opening with respect to a periphery of the upper layer, wherein the opening is configured to receive a tube portion of the feeding tube. The base layer, which includes an upper surface and a lower surface, contains a centrally located opening with respect to a periphery of the base layer, wherein the opening is also configured to receive the tube portion of the feeding tube. Meanwhile, the absorbent material is disposed adjacent the upper layer's lower surface. Further, the cavity permits airflow between the absorbent layer and the base layer when the external bolster is encapsulated by the stoma pad and positioned within the cavity.

The disclosed technology relates to a wound dressing comprising a vertically lapped material. The disclosed technology further relates to methods and uses of the wound dressing.

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting pre-mixed fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

In some examples, a dressing filler for treating a tissue site may include a plurality of filler elements and a tissue interface layer. Each of the filler elements may include a first surface and a second surface opposite the first surface and separated from the first surface by a thickness. The tissue interface layer may include a first side configured to be positioned facing the tissue site and a second side positioned opposite the first side. The first surface of each of the filler elements may be coupled to the second side of the tissue interface layer. Also provided are other apparatuses, dressings, systems, and methods suitable for treating a tissue site.